NCT07421739 Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
| NCT ID | NCT07421739 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aura Biosciences |
| Condition | Choroidal Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-11-12 |
| Primary Completion | 2028-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15 participants in total. It began in 2025-11-12 with a primary completion date of 2028-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.
Eligibility Criteria
Inclusion Criteria: * Have enrolled in the Aura-sponsored clinical trial AU-011-301. * Access to a connected device (i.e., smartphone, laptop, or tablet) Exclusion Criteria: * None
Contact & Investigator
Study Director
STUDY DIRECTOR
Aura Biosciences
Frequently Asked Questions
Who can join the NCT07421739 clinical trial?
This trial is open to participants of all sexes, studying Choroidal Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07421739 currently recruiting?
Yes, NCT07421739 is actively recruiting participants. Contact the research team at clinical@aurabiosciences.com for enrollment information.
Where is the NCT07421739 trial being conducted?
This trial is being conducted at East Melbourne, Australia.
Who is sponsoring the NCT07421739 clinical trial?
NCT07421739 is sponsored by Aura Biosciences. The principal investigator is Study Director at Aura Biosciences. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.